April 30, 2024
National Human Genome Research Institute (NHGRI)
The purpose of this notice is to extend the expiration date for PAR-21-255: Investigator Initiated Research in Computational Genomics and Data Science (R01 Clinical Trial Not Allowed) by one review cycle.
An additional receipt date has been added: October 16, 2024 for new applications and November 16, 2024 for resubmission and revision applications. This Notice of Funding Opportunity now expires on January 8, 2025. The changes below are in bold italics.
The Notice of Funding Opportunity currently reads as:
Part 1. Overview Information, Key Dates
Application Due Date(s): Standard dates apply. The first standard due date for this FOA is Oct 16, 2021.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review: Standard dates apply
Advisory Council Review: Standard dates apply
Earliest Start Date: Standard dates apply
Expiration Date: September 8, 2024
The Notice of Funding Opportunity has been modified as follows:
Part 1. Overview Information, Key Dates
Application Due Date(s): Standard dates apply. The first standard due date for this FOA is Oct 16, 2021.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review: Standard dates apply
Advisory Council Review: Standard dates apply
Earliest Start Date: Standard dates apply
Expiration Date: January 8, 2025
All other aspects of this NOFO remain the same.
Please direct all inquiries to:
Daniel Gilchrist, Ph.D.
National Human Genome Research Institute (NHGRI)
Email: [email protected]